Skip to content
value.today

Micron Biomedical, Inc.

Formerly Micron Biomedical, LLC

Total raised
$32 M
3 rounds on record
Latest round
$15 M
Dec 2024
First round on record
Nov 2022
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Micron Biomedical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$15 MNo. 3$10 to $50 million

Micron Biomedical, Inc.: Raise no. 3, Dec 2024

Investors in this round

3 investors had bought by the notice of Dec 26, 2024: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $16 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Devin McAllister · Executive Officer · Executive Vice President, Chief Technology Officer
  • Henry Sebastien · Executive Officer · Executive Vice President, Head of Technical Operations
  • Idean Marvasty · Executive Officer · Chief Financial Officer
  • Steve Damon · Executive Officer, Director · Chief Executive Officer
  • Bas Van Buijtenen · Director
  • Brian Bernick · Director
  • Labeeb Abboud · Director
  • Mark Prausnitz · Director
  • Matthew Goldman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used for general corporate purposes, including to pay salaries to some related persons listed herein.”

Signed by Idean Marvasty, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 26, 2024. Read the notice at the SEC.

equitySEC
Apr 2023$3 MNo. 2$2 to $10 million

Micron Biomedical, Inc.: Raise no. 2, Apr 2023

Investors in this round

1 investor had bought by the notice of Apr 17, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Devin McAllister · Executive Officer · Executive Vice President, Chief Technology Officer
  • Henry Sebastien · Executive Officer · Executive Vice President, Head of Technical Operations
  • Idean Marvasty · Executive Officer · Chief Financial Officer
  • Steve Damon · Executive Officer, Director · Chief Executive Officer
  • Bas Van Buijtenen · Director
  • Brian Bernick · Director
  • Labeeb Abboud · Director
  • Mark Prausnitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used for general corporate purposes, including to pay salaries to some related persons listed herein.”

Signed by Idean Marvasty, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 17, 2023. Read the notice at the SEC.

equitySEC
Nov 2022$14 MNo. 1$10 to $50 million

Micron Biomedical, Inc.: Raise no. 1, Nov 2022

Investors in this round

4 investors had bought by the notice of Dec 7, 2022: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Devin McAllister · Executive Officer · Executive Vice President, Chief Technology Officer
  • Idean Marvasty · Executive Officer · Chief Financial Officer
  • Sebastien Henry · Executive Officer · Executive Vice President, Head of Technical Operations
  • Steven Damon · Executive Officer, Director · Chief Executive Officer
  • Bas van Buijtenen · Director
  • Labeeb Abboud · Director
  • Mark Prausnitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3.”

Signed by Idean Marvasty, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 7, 2022. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Micron Biomedical, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2024).

    SEC Form D · Dec 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2024

That is all the official record says: Micron Biomedical, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Micron Biomedical, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 4 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Micron Biomedical, Inc.
NameRoleNamed in
Devin McAllisterExecutive Vice President, Chief Technology OfficerDec 2024
Henry SebastienExecutive Vice President, Head of Technical OperationsDec 2024
Idean MarvastyChief Financial OfficerDec 2024
Steve DamonChief Executive OfficerDec 2024
Sebastien HenryExecutive Vice President, Head of Technical OperationsDec 2022
Steven DamonChief Executive OfficerDec 2022
Bas Van BuijtenenDirectorDec 2024
Brian BernickDirectorDec 2024
Labeeb AbboudDirectorDec 2024
Mark PrausnitzDirectorDec 2024
Matthew GoldmanDirectorDec 2024
Steve DamonChief Executive OfficerDec 2024
Bas van BuijtenenDirectorDec 2022
Steven DamonChief Executive OfficerDec 2022